-
HER2-Low Breast Cancer– Pipeline Analytics 2023
$2,500.00 – $7,500.00Select optionsThe 2023 Mellalta Meets report analyzes the HER2-Low Breast Cancer Therapies pipeline, highlighting the market opportunities and competitive landscape with over 30 companies developing pipeline drug profiles. The study marks a significant shift in breast cancer understanding, indicating over 50% of such cancers as HER2-low, thereby creating new prospects for therapeutic ADCs in treating HER2-low tumors. It also details the promising development pipeline involving a variety of ADCs and combination strategies to address this newly classified breast cancer subtype.
-
Anti-Neutralizing Antibodies (NAbs) Gene Therapies-Pipeline Analytics 2022
$2,700.00 – $8,100.00Select optionsAnti-Neutralizing Antibodies (NAbs) Gene Therapies report covers the Anti-Neutralizing Antibodies (NAbs) Gene Therapies market opportunity providing Key Competitive Analysis, 20+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partner as well as Clinical Partner. Reports covers pipeline product analysis by stage of development, competitive landscape by phases, companies, therapy area and indication by phases. NAbs inhibitor’s reports add a value in terms of providing the description of clinical stage product with respect to their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers and challenges.
Call us today: +1 (304) 470-2225
English
You can use WPML or Polylang and their language switchers in this area.
